December 03, 2024FinancialNotice Concerning Status of Acquisition of Own Shares (PDF 88.66 KB) (Acquisition of the Company's own shares under articles of incorporation pursuant to the paragraph 2 of Article 165 of the Companies Act of Japan)
December 03, 2024CorporateMulti-Center Superiority Clinical Trial, Supported by Terumo Blood and Cell Technologies, Aims to Significantly Reduce Complications From Acute Chest Syndrome in Adult Sickle Cell Disease Patients
December 03, 2024CorporateTerumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support CatheterProvides interventionalists with optimal product choices for more complex radial-to-peripheral procedures
Stories Our Technologies Introducing the Terumo Group’s R&D and production engineering initiatives. #12 Personalized Treatment of Liver Cancer Using Microscopic Radioactive Beads #11 Keeping Hope Alive: The Story of the Terumo Implantable Left Ventricular Assist System #10 "Hybrid" Graft Technologies to Support the Evolution of Aortic Treatment #09 Delivering Efficiency and Quality to Cell Therapy Manufacturing #08 Improving Interventional Treatment Quality Pursuing Intravascular Imaging Technology #07 ICT Healthcare Evolution and the State of Pharmaceutical Infusion Systems #06 Terumo Bay Area Innovation Lab A place to create new value #05 Creating Core Technologies to Contribute into the Future #04 Integrating Technologies to Give Diabetes Patients Lifestyle Freedom #03 Technology that Meets Patients’ Medication Needs with Safety and Certainty #02 Continuously Innovating First-in-class Technology to Support Cardiovascular Surgery #01 Intervention through the Wrist Thirty Years of Evolution; More to Come